awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38950577-1ED3A48A-E5FF-4852-B5C0-D8C13001C1D7
Q38950577-1ED3A48A-E5FF-4852-B5C0-D8C13001C1D7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38950577-1ED3A48A-E5FF-4852-B5C0-D8C13001C1D7
Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
P2860
Q38950577-1ED3A48A-E5FF-4852-B5C0-D8C13001C1D7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38950577-1ED3A48A-E5FF-4852-B5C0-D8C13001C1D7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1e1505a0dc3a9016d166f6b5226b6b0f2cc2b5d1
P2860
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.